The startup has developed a drug delivery technology that disrupts pain signals through targeted mechanisms without the use of addictive medications or invasive procedures. This approach is designed for patients suffering from tissue injury, inflammation, or acute nerve damage, providing a non-systemic alternative to opioids and addressing the risks associated with prescription drug abuse.
Funding
$600K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current pain treatments often lack neuron specificity, leading to off-target effects such as addiction, motor neuron inhibition, and damage to surrounding tissues. Existing solutions for disrupting pain signals from peripheral sensory neurons can result in systemic absorption and invasive procedures. This creates a need for targeted pain relief without the risks associated with opioids or other non-specific treatments.
Solution
Neurocarrus is developing N-001, a first-in-class therapeutic designed to selectively disrupt pain signals from sensory nerve cells without systemic absorption or invasive procedures. N-001 utilizes targeted delivery of bacterial proteins to modify the neuron's cytoskeleton, blocking pain signaling. Unlike existing FDA-approved proteins, N-001 specifically affects sensory nerves, leaving motor nerves untouched, thereby avoiding motor-related side effects. This targeted approach aims to treat pain resulting from tissue injury, inflammation, or acute nerve damage, offering a non-addictive alternative to traditional pain management. The Neurocarrus platform is also under evaluation for delivery of other drugs for nerve regeneration and nerve fiber imaging as a surgical adjunct.
Target Audience
The primary target audience includes individuals experiencing pain as a result of tissue injury or inflammation, as well as patients with acute pain, such as post-surgical pain, and clinicians seeking non-addictive pain management solutions.
Features
- Targeted delivery of bacterial proteins to selectively disrupt pain signals in sensory neurons
- Neuron-specific mechanism of action, avoiding off-target effects on motor neurons
- Non-systemic administration to minimize systemic side effects
- Non-addictive pain relief alternative to opioid-based medications
- Potential applications in treating pain from tissue injury, inflammation, and acute nerve damage
- Investigational applications for nerve regeneration and nerve fiber imaging